JP7269167B2 - モジュラー四価二重特異性抗体プラットフォーム - Google Patents
モジュラー四価二重特異性抗体プラットフォーム Download PDFInfo
- Publication number
- JP7269167B2 JP7269167B2 JP2019520024A JP2019520024A JP7269167B2 JP 7269167 B2 JP7269167 B2 JP 7269167B2 JP 2019520024 A JP2019520024 A JP 2019520024A JP 2019520024 A JP2019520024 A JP 2019520024A JP 7269167 B2 JP7269167 B2 JP 7269167B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- domain
- cdrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023069848A JP7796079B2 (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408271P | 2016-10-14 | 2016-10-14 | |
| US62/408,271 | 2016-10-14 | ||
| PCT/US2017/056814 WO2018071913A2 (en) | 2016-10-14 | 2017-10-16 | Modular tetrameric bispecific antibody platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069848A Division JP7796079B2 (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533675A JP2019533675A (ja) | 2019-11-21 |
| JP2019533675A5 JP2019533675A5 (cg-RX-API-DMAC10.html) | 2020-11-26 |
| JP7269167B2 true JP7269167B2 (ja) | 2023-05-08 |
Family
ID=60327374
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520024A Active JP7269167B2 (ja) | 2016-10-14 | 2017-10-16 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2023069848A Active JP7796079B2 (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A Pending JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069848A Active JP7796079B2 (ja) | 2016-10-14 | 2023-04-21 | モジュラー四価二重特異性抗体プラットフォーム |
| JP2025119440A Pending JP2025142045A (ja) | 2016-10-14 | 2025-07-16 | モジュラー四価二重特異性抗体プラットフォーム |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200017588A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3526257A2 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7269167B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN110214152B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017341936B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3038504A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018071913A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3031194A1 (en) * | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| WO2018145075A1 (en) * | 2017-02-06 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
| EP3880247A4 (en) * | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | Bispecific antibodies for activation of immune cells |
| JP2022510218A (ja) * | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| CA3159308A1 (en) * | 2019-12-02 | 2021-06-10 | Wayne A. Marasco | Antibodies against pd-l1 and methods of use thereof |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业(上海)股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2023034288A1 (en) | 2021-08-31 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| AU2023232045A1 (en) | 2022-03-09 | 2024-09-26 | Dana-Farber Cancer Institute, Inc. | Genetically engineered b cells and methods of use thereof |
| CA3263665A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Anti-CLDN4 antibodies and their methods of use |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| CN121399164A (zh) * | 2023-06-20 | 2026-01-23 | 戴纳立制药公司 | 双重转运体及使用方法 |
| WO2026117666A1 (en) * | 2024-11-26 | 2026-06-04 | Dana-Farber Cancer Institute, Inc. | Bispecific antibodies for treating cancer |
| WO2026117664A1 (en) * | 2024-11-26 | 2026-06-04 | Dana-Farber Cancer Institute, Inc. | Engineered cells and uses thereof for treating cancer |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| JP2013515509A (ja) | 2009-12-29 | 2013-05-09 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | ヘテロダイマー結合タンパク質およびその使用 |
| WO2013096346A1 (en) | 2011-12-22 | 2013-06-27 | Development Center For Biotechnology | Bispecific t-cell activator antibody |
| JP2015513394A (ja) | 2012-02-13 | 2015-05-14 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネ | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2015197582A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| JP2016516049A (ja) | 2013-03-15 | 2016-06-02 | メモリアル スローン−ケタリング キャンサー センター | 多量体化技術 |
| JP2016526878A (ja) | 2013-05-20 | 2016-09-08 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及び使用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN1914226B (zh) | 2003-11-25 | 2012-02-01 | 达纳-法伯癌症研究院有限公司 | SARS-CoV抗体及其使用方法 |
| EP1695093A1 (en) * | 2003-12-05 | 2006-08-30 | multimmune GmbH | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases |
| US8329178B2 (en) | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| JP2011524966A (ja) * | 2008-02-22 | 2011-09-08 | ダウ グローバル テクノロジーズ エルエルシー | 熱エネルギー貯蔵材料 |
| EP3957653A1 (en) | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| CN103906533A (zh) * | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| EP2794662A1 (en) * | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| EP2850106B1 (en) * | 2012-05-18 | 2022-03-23 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| EP2920210B1 (en) * | 2012-11-19 | 2017-08-30 | Baliopharm AG | Recombinant bispecific antibody binding to cd20 and cd95 |
| EP4292657A3 (en) | 2013-03-15 | 2024-03-20 | Dana Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| AR097306A1 (es) * | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| KR20160122127A (ko) * | 2013-12-23 | 2016-10-21 | 자임워크스 인코포레이티드 | C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법 |
| EP3119804A2 (en) | 2014-03-19 | 2017-01-25 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| WO2015164865A1 (en) | 2014-04-25 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
| PL3151921T3 (pl) * | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| CA2962949C (en) | 2014-10-06 | 2024-03-05 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| US11135282B2 (en) | 2015-04-08 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| JP7649239B2 (ja) * | 2018-11-30 | 2025-03-19 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | キメラ抗原受容体ファクトリおよびその使用方法 |
-
2017
- 2017-10-16 EP EP17798026.5A patent/EP3526257A2/en active Pending
- 2017-10-16 US US16/340,878 patent/US20200017588A1/en not_active Abandoned
- 2017-10-16 JP JP2019520024A patent/JP7269167B2/ja active Active
- 2017-10-16 CN CN201780067582.7A patent/CN110214152B/zh active Active
- 2017-10-16 CA CA3038504A patent/CA3038504A1/en active Pending
- 2017-10-16 CN CN202510732184.9A patent/CN120795163A/zh active Pending
- 2017-10-16 AU AU2017341936A patent/AU2017341936B2/en active Active
- 2017-10-16 WO PCT/US2017/056814 patent/WO2018071913A2/en not_active Ceased
-
2023
- 2023-04-21 JP JP2023069848A patent/JP7796079B2/ja active Active
-
2025
- 2025-01-31 AU AU2025200665A patent/AU2025200665A1/en active Pending
- 2025-07-16 JP JP2025119440A patent/JP2025142045A/ja active Pending
- 2025-09-03 US US19/318,009 patent/US20260193357A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| JP2013515509A (ja) | 2009-12-29 | 2013-05-09 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | ヘテロダイマー結合タンパク質およびその使用 |
| WO2013096346A1 (en) | 2011-12-22 | 2013-06-27 | Development Center For Biotechnology | Bispecific t-cell activator antibody |
| JP2015513394A (ja) | 2012-02-13 | 2015-05-14 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネ | 二重特異性キメラ抗原受容体およびその治療的使用 |
| JP2016516049A (ja) | 2013-03-15 | 2016-06-02 | メモリアル スローン−ケタリング キャンサー センター | 多量体化技術 |
| JP2016526878A (ja) | 2013-05-20 | 2016-09-08 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及び使用方法 |
| WO2015197582A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
Non-Patent Citations (1)
| Title |
|---|
| FEBS LETTERS,1998年07月,Vol. 432, No. 1-2,pp. 45-49 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019533675A (ja) | 2019-11-21 |
| CN110214152A (zh) | 2019-09-06 |
| EP3526257A2 (en) | 2019-08-21 |
| AU2025200665A1 (en) | 2025-04-10 |
| US20260193357A1 (en) | 2026-07-09 |
| CN120795163A (zh) | 2025-10-17 |
| WO2018071913A2 (en) | 2018-04-19 |
| US20200017588A1 (en) | 2020-01-16 |
| JP2023093642A (ja) | 2023-07-04 |
| WO2018071913A3 (en) | 2018-05-24 |
| AU2017341936A1 (en) | 2019-04-04 |
| CN110214152B (zh) | 2025-06-13 |
| JP2025142045A (ja) | 2025-09-29 |
| JP7796079B2 (ja) | 2026-01-08 |
| CA3038504A1 (en) | 2018-04-19 |
| AU2017341936B2 (en) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110214152B (zh) | 模块化四聚体双特异性抗体平台 | |
| AU2020286284B2 (en) | Novel anti-CD39 antibodies | |
| JP7862028B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| CN113166262B (zh) | Pd-1单结构域抗体及其治疗组合物 | |
| TWI919523B (zh) | 5t4單域抗體及其治療性組合物 | |
| CN115380047A (zh) | Cd28单结构域抗体及其多价和多特异性构建体 | |
| CN111133003A (zh) | 新型双特异性多肽复合物 | |
| TW202144437A (zh) | 靶向ox40及fap之雙特異性抗原結合分子 | |
| JP2021521784A (ja) | IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用 | |
| KR20200104305A (ko) | 삼중 사슬 항체(Triple-Chain Antibody)의 제조 방법 및 용도 | |
| KR102887991B1 (ko) | 이중특이적 항pd-1 tim3 항체 | |
| JP7462611B2 (ja) | Ox40結合性ポリペプチド及びその使用 | |
| CN115484981A (zh) | 用于调节免疫应答的材料和方法 | |
| AU2017233658A1 (en) | Cell injury inducing therapeutic drug for use in cancer therapy | |
| CN114127112A (zh) | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 | |
| TW202216745A (zh) | 包含經修飾il-2多肽之多肽及其用途 | |
| WO2022006451A2 (en) | Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies | |
| WO2022111576A1 (en) | Novel conjugate molecules targeting cd39 and tgfβeta | |
| KR20230047009A (ko) | 암의 치료에 이용하기 위한 세포 상해 유도 치료제 | |
| KR20230156727A (ko) | 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도 | |
| HK40085531A (en) | Materials and methods for modulating an immune response | |
| HK40010370A (en) | Tri-chain antibody, preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201013 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201013 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210622 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210730 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210811 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220622 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220921 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230323 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230421 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7269167 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |